Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

Xenobiotica

Volumn 41, Issue 12, 2011, Pages 1044-1055

  Fedejko Kap, Barbara ^a   Niemira, Magdalena ^a   Radominska Pandya, Anna ^b   Mazerska, Zofia ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anti tumour drug; C 1305; CYP inhibition; FMO metabolism; HepG2 metabolism; P450 isoenzymes; Triazoloacridinone

Indexed keywords

ANTINEOPLASTIC AGENT; C 1299; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; FLAVIN MONOOXYGENASE 1; FLAVIN MONOOXYGENASE 3; N OXIDE DERIVATIVE; OXIDE; QUERCETIN; TRIAZOLOACRIDINONE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ENZYME DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYPOXIA; LIVER MICROSOME; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT;

ACRIDINES; AMINOACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOCATALYSIS; BIOTRANSFORMATION; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; KINETICS; MICROSOMES, LIVER; OXYGENASES; RATS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DONORS; TRIAZOLES;

RATTUS;

EID: 80655125270     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.604743     Document Type: Article

References (32)

1. Augustin E, Mos-Rompa A, Skwarska A, Witkowski JM, Konopa J. (2006). Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72:1668-1679. (Pubitemid 44765001)
2. Bidzinska J, Wojciechowski M, Baginski M, Skladanowski A. (2009). Specifc structural changes in telomeric DNA induced by triazoloacridone compound C-1305 prevent the formation of TRF1/2 shelterin complexes. Mol Cancer Ter, 8(12 Suppl), C159.
3. Boocock DJ, Maggs JL, White IN, Park BK. (1999). α- hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identifcation and quantifcation in vivo and in vitro. Carcinogenesis 20:153-160. (Pubitemid 29033858)
4. Capizzi RL, Roman LA, Tjulandin S, Smirnova I, Manikhas A, Paterson JS, Major A, Lundberg AS, Fumoleau P. (2008). Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. J Clin Oncol 26 (suppl), 1055.
5. Cashman JR. (2005). Some distinctions between favin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:599-604. (Pubitemid 41540608)
6. Cholody WM, Martelli S, Konopa J. (1990). 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem 33:2852-2856. (Pubitemid 20312155)
7. Cholody WM, Martelli S, Paradziej-Lukowicz J, Konopa J. (1990). 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33:49-52. (Pubitemid 20038169)
8. Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. (2003). In vitro inhibitory efect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: A comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287-295.
9. Grimm SW, Dyrof MC. (1997). Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598-602. (Pubitemid 27213101)
10. Huang Q, Stoner G, Resau J, Nickols J, Mirvish SS. (1992). Metabolism of N-nitrosomethyl-n-amylamine by microsomes from human and rat esophagus. Cancer Res 52:3547-3551.
11. Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, Loadman P, Capizzi R, Grieshaber C, Fumoleau P.(2010). Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer 46:729-734.
12. Jacobson PA, Green K, Birnbaum A, Remmel RP. (2002). Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 49:461-467. (Pubitemid 34671281)
13. Koba M, Konopa J. (2007). Interactions of antitumor triazoloacridinones with DNA. Acta Biochim Pol 54:297-306. (Pubitemid 47057873)
14. Kousba A, Soll R, Yee S, Martin M. (2007). Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3- yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and its N-oxide metabolite by favin-containing monoxygenases and cytochrome P450 reductase. Drug Metab Dispos 35:2242-2251. (Pubitemid 350146211)
15. Krueger SK, Williams DE. (2005). Mammalian favin-containing monooxygenases: Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ter 106:357-387. (Pubitemid 40726294)
16. Krueger SK, Vandyke JE, Williams DE, Hines RN. (2006). Te role of favin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab Rev 38:139-147. (Pubitemid 43739004)
17. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J. (1994). Experimental antitumor activity and toxicity of the selected triazolo-and imidazoacridinones. Arch Immunol Ter Exp (Warsz) 42:415-423.
18. Lee JW, Shin KD, Lee M, Kim EJ, Han SS, Han MY, Ha H, Jeong TC, Koh WS. (2003). Role of metabolism by favin-containing monooxygenase in thioacetamide-induced immunosuppression. Toxicol Lett 136:163-172. (Pubitemid 36005464)
19. Lemke K, Poindessous V, Skladanowski A, Larsen AK. (2004). Te antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66:1035-1042. (Pubitemid 39319476)
20. Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, Larsen AK, Skladanowski A. (2005). Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res 33:6034-6047. (Pubitemid 41742622)
21. Murray M. (1997). Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 24:465-470. (Pubitemid 27273820)
22. Parte P, Kupfer D. (2005). Oxidation of tamoxifen by human favin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33:1446-1452. (Pubitemid 41323991)
23. Phillips IR, Shephard EA. (2008). Flavin-containing monooxygenases: Mutations, disease and drug response. Trends Pharmacol Sci 29:294-301.
24. Pike MG, Mays DC, Macomber DW, Lipsky JJ. (2001). Metabolism of a disulfram metabolite, S-methyl N,N-diethyldithiocarbamate, by favin monooxygenase in human renal microsomes. Drug Metab Dispos 29:127-132. (Pubitemid 32112925)
25. Potega A, Dabrowska E, Niemira M, Kot-Wasik A, Ronseaux S, Henderson CJ, Wolf CR, Mazerska Z. (2011). Te imidazoacridinone antitumor drug, C-1311, is metabolized by favin mono-oxygenases but not by cytochrome p450s. Drug Metab Dispos 39: 1423-1432.
26. Richter T, Schwab M, Eichelbaum M, Zanger UM. (2005). Inhibition of human CYP2B6 by N,N',N"-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517-524. (Pubitemid 40094510)
27. Solomon H, Brosh R, Buganim Y, Rotter V.(2010). Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. Discov Med 9:448-454.
28. Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. (2002). Efect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ter 301:945-952. (Pubitemid 34595084)
29. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. (2004). Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112. (Pubitemid 38112542)
30. Wesierska-Gadek J, Schlofer D, Gueorguieva M, Uhl M, Skladanowski A.(2004). Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacri-done C-1305 is asso-ciated with permanent G2 cell cycle arrest. Cancer Res. 64: 4487-4497. (Pubitemid 38856920)
31. Wisniewska A, Chrapkowska A, Kot-Wasik A, Konopa J, Mazerska Z. (2007). Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver. Acta Biochim Pol 54:831-838.
32. Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK Jr, Takker DR. (2008). Role of favin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 36:1119-1125. (Pubitemid 351717470)